BMEA (Biomea Fusion) ROCE %: -120.85% (As of Mar. 2026)


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.31
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion ROCE %?

Biomea Fusion BMEA +6.10% 31 ROCE % is -120.85% as of Mar. 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biomea Fusion's annualized ROCE % for the quarter that ended in Mar. 2026 was -120.85%.

Biomea Fusion  (NAS:BMEA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biomea Fusion ROCE % Related Terms

Biomea Fusion ROCE % Historical Data

* Premium members only.

The historical data trend for Biomea Fusion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomea Fusion ROCE % Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -34.44 -57.43 -87.82 -122.44 -153.79

Biomea Fusion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -254.21 -187.39 -156.27 -107.65 -120.85
BMEA
31GF Score
Biomea Fusion Inc BMEA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomea Fusion ROCE % Calculation

Biomea Fusion's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-81.307/( ( (79.938 - 21.673) + (58.572 - 11.101) )/ 2 )
=-81.307/( (58.265+47.471)/ 2 )
=-81.307/52.868
=-153.79 %

Biomea Fusion's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-51.096/( ( (58.572 - 11.101) + (46.385 - 9.294) )/ 2 )
=-51.096/( ( 47.471 + 37.091 )/ 2 )
=-51.096/42.281
=-120.85 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -120.85% mean?
Biomea Fusion (BMEA) has a ROCE % of -120.85% as of Mar. 2026.
Is Biomea Fusion's ROCE % too high?
Biomea Fusion's current ROCE % is -120.85%. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's ROCE % compare to VRCA and PMN?
Biomea Fusion's ROCE % of -120.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Biomea Fusion's current ROCE % is -120.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current ROCE % of -120.85%. The current ROCE % is -120.85%. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current ROCE % is -120.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price